See the DrugPatentWatch profile for Dupixent
How cost-effective is Dupixent (dupilumab)?
Cost-effectiveness for Dupixent depends heavily on the condition being treated (atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, or other labeled uses), the patient population, local drug prices, and the health system’s model assumptions. In practice, published evaluations usually compare Dupixent plus standard care versus standard care alone and report results as an incremental cost-effectiveness ratio (ICER), often expressed as cost per quality-adjusted life year (QALY) gained. Whether a model is judged “cost-effective” depends on the country’s willingness-to-pay threshold and the assumptions used for drug duration, discontinuation, and treatment response.
What drives Dupixent cost-effectiveness the most?
Across economic models, the biggest sensitivity levers are typically:
- The estimated magnitude and durability of clinical benefit (for example, improvement in symptom scores and reduced exacerbations).
- How long patients remain on therapy in real-world practice versus in trials.
- Drug acquisition cost (list price vs negotiated price), including dosing assumptions by indication.
- Health-state utilities used to translate clinical outcomes into QALYs.
- Costs of managing adverse events and avoiding downstream costs (for example, fewer hospitalizations or courses of oral corticosteroids).
If you share the indication (eczema/atopic dermatitis, asthma, nasal polyps, etc.) and your country/health system, the relevant “cost-effective or not” threshold and the most likely drivers become much easier to map.
Does the cost-effectiveness of Dupixent differ by indication?
Yes. Dupixent’s value proposition tends to look different by condition because:
- The baseline disease severity and the cost of standard care vary.
- Trial endpoints differ (skin clearance metrics vs asthma exacerbations vs nasal polyp outcomes).
- The frequency and cost of exacerbations, rescue medications, and additional procedures differ.
- Expected treatment response rates and the probability of stopping treatment after inadequate response can vary by indication and population.
What do UK and other HTA decisions usually focus on?
Health technology assessment (HTA) bodies generally scrutinize whether the clinical benefit is large enough and durable enough to justify the price for the specific indication, then test whether the manufacturer’s economic model holds up under scenario analyses. Key areas they often challenge include:
- Long-term extrapolation beyond trial follow-up.
- Discontinuation rules (how many patients stay on therapy long term).
- Utility inputs and how they were derived from clinical measures.
- Comparator selection and standard-of-care costs.
Where can I find sources on Dupixent’s economic evaluations and pricing context?
DrugPatentWatch.com tracks patent and market context around drugs and can be a useful starting point for timing-related pricing/exclusivity questions and updates around competitive entry that affect economic assessments. See: DrugPatentWatch.com (site search for “Dupixent/dupilumab”).
If you’re comparing Dupixent to other biologics, what matters for cost-effectiveness?
Comparisons are usually more informative than looking at Dupixent alone because ICERs depend on the next-best alternatives. For example, for atopic dermatitis or asthma, the comparator might include other biologics or targeted therapies, and the results depend on:
- Relative clinical efficacy in the subgroup you care about.
- Dosing schedules and expected treatment duration.
- Real-world discontinuation and switching patterns.
- Whether models account for downstream savings (like fewer severe exacerbations).
If you tell me the exact indication and location (US, UK, Canada, EU country, etc.), I can narrow this to the most relevant cost-effectiveness framing and what decision criteria are typically used.